Devyser Diagnostics AB (publ) (DVYSR.ST)
SEK 117.0
(0.0%)
SEK 117.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -56.5 Million SEK | -2.82% |
| 2022 | -54.94 Million SEK | -151.94% |
| 2021 | -21.81 Million SEK | -213.54% |
| 2020 | -6.95 Million SEK | -180.43% |
| 2019 | 8.64 Million SEK | 346.38% |
| 2018 | -3.51 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -22.2 Million SEK | -38.75% |
| 2024 Q3 | -20.7 Million SEK | -6.76% |
| 2024 Q1 | -16 Million SEK | -6.67% |
| 2023 FY | -56.5 Million SEK | -2.82% |
| 2023 Q1 | -19.1 Million SEK | 23.75% |
| 2023 Q4 | -15 Million SEK | -127.27% |
| 2023 Q3 | -6.6 Million SEK | 58.23% |
| 2023 Q2 | -15.8 Million SEK | 17.28% |
| 2022 Q1 | -6.8 Million SEK | 52.15% |
| 2022 FY | -54.94 Million SEK | -151.94% |
| 2022 Q3 | -9.2 Million SEK | 33.33% |
| 2022 Q4 | -25.04 Million SEK | -172.26% |
| 2022 Q2 | -13.8 Million SEK | -102.94% |
| 2021 Q4 | -14.21 Million SEK | 0.0% |
| 2021 FY | -21.81 Million SEK | -213.54% |
| 2020 FY | -6.95 Million SEK | -180.43% |
| 2019 FY | 8.64 Million SEK | 346.38% |
| 2018 FY | -3.51 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AroCell AB (publ) | -59.78 Million SEK | 5.493% |
| Immunovia AB (publ) | -296.46 Million SEK | 80.942% |
| Prostatype Genomics AB (publ) | -39.3 Million SEK | -43.744% |
| SenzaGen AB | -14.74 Million SEK | -283.311% |
| Spermosens AB | -10.89 Million SEK | -418.634% |